MRNA (Moderna, Inc.) Short-Term Debt to Capital

Moderna, Inc. (MRNA) is leveraging the power of its mRNA platform to expand into the oncology and respiratory vaccine segments. The short-term debt-to-equity ratio on the GURU.Markets chart demonstrates current financial stability, where the 0.01 metric determines this level. Growth potential depends on FDA approval of new drugs and mitigating the decline in COVID-19 sales amid severe market pressure.

For Moderna, Inc. (MRNA), the chart of the ratio between short-term liabilities and equity reflects current financial stability during the commercialization of mRNA drugs. This metric assesses the share of obligations maturing within one year relative to shareholders' equity, revealing the dependence on rapid borrowing. Low values confirm a sufficient liquidity buffer to fund the development of cancer and RSV vaccines. A stable trend guarantees protection against defaults and confirms the issuer's solvency.